## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 10/544213

KARKI ET AL. Applicants:

Serial No. **TBA** 

Filed:

FORMULATIONS FOR TYROSINE KINASE

**INHIBITORS** 

Art Unit:	TBA	 
Examiner:	TBA	

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

## INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR 1.97**

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

## INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED APPLICATION			
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE		

L			l
if ti	nis is inconvenient, additional copies will be submitted upon reques	st.	
	6. In accordance with 37 C.F.R. 1.97, (check one)		
$\checkmark$	the attached information is filed within three months of the filing da	ate of the captioned case.	
	the attached information is filed more than three months after the Office Action on the merits.	filing date but prior to the m	ailing of a first
	the attached information is being filed more than three months after Office Action on the merits, but before the mailing date of a Final Action authorization is therefore given to charge Deposit Account No. 13-	Action or Notice of Allowand	e. The enclosed
	1.17(p). the undersigned certifies that each item of information contained in cited in any communication from a foreign patent office in a counter months prior to the filing of this Statement.		
	the undersigned certifies that no item of information contained in to a communication from a foreign patent office in a counterpart fore person signing the certification after making reasonable inquiry, we C.F.R. 1.56(c) more than three months prior to the filing of this Sta	ign application, and, to the last known to any individual c	nowledge of the
		Respectfully submitted,	
		By: Sylvia A. Ayler	
		Attorney For Appl	icant(s)
		Reg. No. 36,436	_
		MERCK & CO., INC.	
		Patent Dept., RY60-30	
		P.O. Box 2000 Rahway, N.J. 07065-0907	
		(732)594- <u>4909</u>	
		Date: August 2, 2005	

'					FRIENT BE TIMENER OF COMMERCE	
	Substitute for form 1449A/PTO		COMPLETE IF KNOWN			
	INFORMATION	DIS	LOSURE	Application Number	тва 10/544213	
		Filing Date JC18 R	C'd PCT/PTO 02-AUG 2005			
	STATEMENT BY APPLICANT		PLICANI	First Named Inventor	Karki et al.	
				Group Art Unit	тва	
-	(use as many sheets as necessary)		Examiner Name	тва		
Sheet	1	of	2	Attorney Docket Number	21346P	

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY	
	ĺ	6245759		Bilodeau et al.	06/12/2001	
		6306874		Fraley et al.	10/23/2001	
I						
· · · · · · · · ·		· · · · · · · · ·				
•						
		<u> </u>		<u></u>	<u> </u>	

	FOREIGN PATENT DOCUMENTS						
			Foreign Patent Documen	t		Date of Publication of	
Examiner Initials*	Examiner Cite Initials* No. Office	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	
	-						

Examiner Signature Date Considered

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY A BRILICANT		Application Confidence	TBA 10/544213		
		Filing Date	GICTIPIO G 2 AUG 2005		
3	STATEMENT BY APPLICANT			First Named Inventor	Karki et al. 2005
_				Group Art Unit	ТВА
	(use as many sheets	as n	ecessary)	Examiner Name	ТВА
Sheet	2	of	2	Attorney Docket Number	21346P

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		K. J. Kim et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in Vivo", 1993, pp. 841-844, Vol. 362, Nature.
		N. Weidner et al., "Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma", 1991, pp. 1-8, Vol. 324, The New Eng. J. of Medicine.
. 1100		
-		

Examiner	Date
Signature	Considered

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form \*IDS Form\* (IDS Folder), Merck & Co., Inc., -7/12/2005)